Hogan Lovells advised EyePoint Pharmaceuticals on the offering. Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a clinical-stage biopharmaceutical company, announced its US$161 million follow-on public offering of 14,636,363...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
